A Phase I study of safety, pharmacokinetics, and pharmacodynamics of concurrent everolimus and buparlisib treatment in advanced solid tumors.

CONCLUSION: The combination of everolimus and buparlisib is safe and well-tolerated at the RP2D of 5mg and 60mg on a continuous daily schedule.
PMID: 32005746 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 30, 2020 Category: Cancer & Oncology Authors: Owonikoko TK, Harvey RD, Carthon B, Chen Z, Lewis C, Collins H, Zhang C, Lawson DH, Alese OB, Bilen MA, Sica GL, Steuer CE, Shaib WL, Wu C, Harris WB, Akce M, Kudchagkar RR, El-Rayes BF, Lonial S, Ramalingam SS, Khuri FR Tags: Clin Cancer Res Source Type: research